Huawei CEO Ren Zhengfei said in an interview with CNBC the company's business is still strong in China.Technologyread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
U.S. President Donald Trump officially kicked off his reelection campaign Tuesday at a Florida rally where he exhorted thousands of rollicking supporters to keep advancing his...Politicsread more
Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
Sen. Josh Hawley, a well-known tech critic, introduced legislation on Wednesday that would remove the immunity big technology companies receive for user-posted content under...Technologyread more
Facebook's new cryptocurrency project, titled Libra and backed by the likes of Visa and Booking Holdings, is being widely embraced by market watchers.Trading Nationread more
Zuckerberg fell out of Glassdoor's top 20 CEO ranking for the first time, although his employee approval rate remains high.Technologyread more
The U.S. and China have imposed tariffs on billions of dollars' worth of one another's goods since the start of 2018.Traderead more
More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
Adobe expects fiscal third-quarter earnings and revenue that are below what analysts were looking for.Technologyread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
OxyContin-maker Purdue Pharma is exploring bankruptcy protection amid accusations of igniting a nationwide opioid crisis by ruthlessly marketing and misleading doctors and patients about the dangers of the highly addictive narcotic.
Purdue, founded in the 1950s by brothers Arthur, Mortimer and Raymond Sackler, is looking at filing for Chapter 11 bankruptcy to protect its assets against thousands of lawsuits for its role in the opioid epidemic, according to a Reuters report.
A bankruptcy filing is not certain, Reuters reported, citing anonymous sources. Purdue Pharma has not made any final decisions and could instead continue fighting the lawsuits, Reuters said.
"As a privately-held company, it has been Purdue Pharma's longstanding policy not to comment on our financial or legal strategy," Purdue said in a statement. "We are, however, committed to ensuring that our business remains strong and sustainable. We have ample liquidity and remain committed to meeting our obligations to the patients who benefit from our medicines, our suppliers and other business partners."
Purdue and other manufacturers face a trial in May in a case brought by Oklahoma Attorney General Mike Hunter. Accusations against the Stamford, Connecticut-based company include downplaying the addiction risk while overstating the benefits of opioids.
They've also been accused of urging sales representatives to advise doctors to prescribe the highest dosage of the painkiller because it was more profitable.
The company has denied any wrongdoing. They say labels for its painkiller carried warnings about the risk of abuse and misuse associated with the drugs.
OxyContin is a prescription drug used to treat moderate to severe pain in adults. From 1999 to 2017, nearly 218,000 people have died in the United States from overdoses related to prescription opioids, according to the U.S. Centers for Disease Control and Prevention. OxyContin first came on the market in 1996.
In late 2017, Purdue launched an advertising campaign meant to show it is doing its part to stem the epidemic. The ads, which appeared in several national and public newspapers, emphasized that the company is a "research-driven, science-based" entity and dedicated to discovering safer new pain medications.